Search
Results: 1
Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.
Osman Aksoy, Jan Pencik, Markus Hartenbach, Ali A Moazzami, Michaela Schlederer, Theresa Balber, Adam Varady, Cecile Philippe, Pascal A Baltzer, Bismoy Mazumder, Jonathan B Whitchurch, Christopher J Roberts, Andrea Haitel, Merima Herac, Martin Susani, Markus Mitterhauser, Rodrig Marculescu, Judith Stangl-Kremser, Melanie R Hassler, Gero Kramer, Shahrokh F Shariat, Suzanne D Turner, Boris Tichy, Jan Oppelt, Sarka Pospisilova, Sabrina Hartenbach, Simone Tangermann, Gerda Egger, Heidi A Neubauer, Richard Moriggl, Zoran Culig, Georg Greiner, Gregor Hoermann, Marcus Hacker, David M Heery, Olaf Merkel, Lukas Kenner
Sep 03, 2020
Androgen deprivation therapy (ADT) remains a key approach in the treatment of prostate cancer (PCa). However, PCa inevitably relapses and becomes ADT resistant. Besides androgens, there is evidence that thyroid hormone thyroxine...
PSMA-PET Androgen receptor prostate cancer thyroid hormone receptor μ-Crystallin Cell Line Tumor Choline Cohort Studies Crystallins Down-Regulation Gene Expression Profiling Gene Expression Regulation Neoplastic Humans Male Metabolomics Neoplasm Staging PC-3 Cells Positron Emission Tomography Computed Tomography Prognosis Prostatic Neoplasms Receptors Androgen Receptors Thyroid Hormone Sequence Analysis RNA Signal Transduction Tissue Array Analysis Triiodothyronine mu-Crystallins